Epoch Biotech

Epoch Biotech is a preclinical-stage biotechnology company focused on developing novel therapeutics for Alzheimer's disease. Founded in 2022, the company's research is inspired by the protective biology of the APOE Christchurch genetic variant, which is associated with profound resilience against Alzheimer's disease. Epoch Biotech's lead program is 7C11, a humanized monoclonal antibody licensed from Massachusetts General Brigham that mimics the protective effects of the Christchurch variant by blocking pathological interactions between apolipoprotein E (APOE) and heparan sulfate proteoglycans (HSPGs). This mechanism aims to reduce tau pathology, neuroinflammation, and cerebrovascular dysfunction to delay, prevent, and treat both familial and sporadic Alzheimer's disease.